

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 6185)**

**CLARIFICATION ANNOUNCEMENT**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company has noticed certain misleading media reports related to the clinical trials for Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (the “**Ad5-nCoV**”) in Canada.

The Company hereby makes following statements and clarifications to prevent the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company from being misled:

1. Up to the date of this announcement, the collaboration between the National Research Council of Canada and the Company has not been terminated. None of the management of the Company has accepted any interview in relation to the clinical trails for Ad5-nCoV in Canada in the recent period; and
2. The Company is currently driving the international multi-center phase III clinical trial for Ad5-nCoV with several countries.

Save as disclosed in this announcement, after having made all reasonable enquiries with the Company, the Board of Directors confirms that it is not aware of any other information which must be announced to avoid a false market in the Company's securities or any inside information that needs to be disclosed under the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) under Part XIVA of the Securities and Futures Ordinance.

**Cautionary Statement required by Rule 18A.05 of the Listing Rules:** The safety and efficacy of Ad5-nCoV are subject to confirmation by clinical trials and we cannot guarantee that we will ultimately develop or commercialize Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, August 27, 2020

*As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.*